AlphaCore Capital LLC Grows Stock Holdings in Takeda Pharmaceutical Co. $TAK

AlphaCore Capital LLC boosted its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 216.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,358 shares of the company’s stock after acquiring an additional 26,933 shares during the period. AlphaCore Capital LLC’s holdings in Takeda Pharmaceutical were worth $576,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TAK. Bank of America Corp DE increased its holdings in shares of Takeda Pharmaceutical by 225.8% in the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock valued at $16,035,000 after purchasing an additional 718,805 shares during the period. Goldman Sachs Group Inc. increased its stake in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares during the period. ABC Arbitrage SA acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at $8,372,000. Quantinno Capital Management LP raised its position in Takeda Pharmaceutical by 54.5% during the 2nd quarter. Quantinno Capital Management LP now owns 797,036 shares of the company’s stock worth $12,322,000 after buying an additional 280,992 shares during the last quarter. Finally, Brandes Investment Partners LP lifted its stake in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock worth $57,392,000 after acquiring an additional 208,136 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $18.74 on Friday. The firm has a market capitalization of $59.61 billion, a PE ratio of 78.07 and a beta of 0.02. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.82. The firm’s 50-day simple moving average is $16.94 and its 200 day simple moving average is $15.35. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $7.81 billion. On average, equities research analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley started coverage on Takeda Pharmaceutical in a report on Tuesday, January 13th. They issued an “overweight” rating on the stock. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.